Guardant Health (GH) came out with a quarterly loss of $1.58 per share versus the Zacks Consensus Estimate of a loss of $0.93. This compares to loss of $1.36 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -69.89%. A quarter ago, it was expected that this provider of oncology testing services would post a loss of $0.93 per share when it actually produced a loss of $0.73, delivering a surprise of 21.51%.Over the last four quart ...

Guardant Health (GH) closed the last trading session at $22.66, gaining 0.5% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $47.56 indicates a 109.9% upside potential.The average comprises 16 short-term price targets ranging from a low of $27 to a high of $64, with a standard deviation of $10.63. While the lowest estimate indicates an increase of 19.2% from the current price level ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 _____________________ FORM 10-K _____________________ (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38683 GUARDANT HEALTH, INC. (Exact Name of Registrant as Specified in its Charter) _______ ...

Guardant Health业绩预测 - Guardant Health (GH) 预计在2023年12月报告的季度业绩中，盈利将同比增长，收入也将增加[1] - 如果关键数据超过预期，股价可能会上涨；反之，可能会下跌[2] 分析师预期 - 分析师最近对公司的盈利前景变得乐观，因此预计其将超过共识EPS估计[12] - Guardant Health 在过去四个季度中，三次超过共识EPS估计[14]

Guardant Health (GH) has been beaten down lately with too much selling pressure. While the stock has lost 12.9% over the past four weeks, there is light at the end of the tunnel as it is now in oversold territory and Wall Street analysts expect the company to report better earnings than they predicted earlier.Here is How to Spot Oversold StocksWe use Relative Strength Index (RSI), one of the most commonly used technical indicators, for spotting whether a stock is oversold. This is a momentum oscillator that ...

PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, will present interim data from the COSMOS study supporting the use of Guardant Reveal to predict disease recurrence in patients with early-stage colon cancer at the ASCO 2024 Gastrointestinal Cancers Symposium, January 18-20 in San Francisco. Guardant Reveal analyzes comprehensive molecular signals in the blood to detect and quantify minimal residual disease (MRD). The COSMOS study evaluated the ...

PALO ALTO, Calif., Jan. 8, 2024 /PRNewswire/ -- Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, and Hikma Pharmaceuticals PLC ("Hikma"), a multinational pharmaceutical company, today announced an agreement to promote Guardant Health's portfolio of liquid and tissue biopsy tests for cancer screening, recurrence monitoring and tumor mutation profiling for all solid cancers across the Middle East and North Africa (MENA). The partnership expands Guardant Health's global presence and in ...

PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the addition of Terilyn Juarez Monroe as the company’s chief people officer, effective immediately. In the newly-created role, Monroe will lead the human resources function, including people operations; cultural and organizational transformation; talent acquisition; and diversity and inclusion initiatives. Amelia Merrill, who previously served as senior vice president of people, i ...

PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that it has entered into a common stock purchase agreement with Baillie Gifford on behalf of accounts that it manages for the sale of 3,387,446 shares of its common stock in a registered direct offering at an offering price of $26.77 per share. Gross proceeds are approximately $90.7 million, before deducting expenses payable by Guardant Health. Guardant Health intends to use the n ...

财务数据和关键指标变化 - 第三季度总收入增长22%至1.43亿美元,精准肿瘤检测业务收入增长31% [14][50][54] - 临床检测量增长35%至43,900例,主要由Guardant360带动 [15][55] - Guardant360 ASP预计将从第四季度的2,700-2,750美元增至2024年1月1日起的2,850-2,900美元,主要受益于Medicare价格上调 [50][51][52][53] - 毛利率为60%,与去年同期相比略有下降,主要由于产品组合变化 [62][63] - 经营费用同比下降10%,净亏损同比减少47% [63][64] 各条业务线数据和关键指标变化 - 精准肿瘤检测业务中,临床检测收入增长34%,临床检测量增长35% [55][56] - 生物制药检测收入增长22%,检测量增长11% [59] - 开发服务及其他收入同比下降37%,主要由于合作项目里程碑收入时间性变化 [60][61] 各个市场数据和关键指标变化 - 国际市场收入占比较小,但预计未来一年内将实现显著增长 [23][24] - 日本市场是公司最大的国际扩张机会,Guardant360 CDx近期获得监管和报销批准 [24] 公司战略和发展方向及行业竞争 - 公司致力于通过液体活检技术转变肿瘤诊断,在治疗选择、微小残留病灶检测和筛查等领域拥有广阔机会 [9][69] - 公司正在持续提升Guardant360和Reveal的性能,并计划将Shield扩展至肺癌等其他适应症 [40][41][42][47] - 公司在与主要医疗机构EMR系统集成,预计将提升订单量 [19][20][21] - 公司正在推动各州通过生物标志物检测报销法案,以扩大私人保险报销覆盖 [27][28][29] 管理层对经营环境和未来前景的评论 - 公司对长期发展前景充满信心,认为目前才刚刚触及巨大机会的表面 [9][10] - 管理层对Guardant360 ASP未来的持续提升表示乐观,预计可达3,000美元以上 [51][52][53] - 管理层认为公司当前现金储备可提供实现现金流平衡所需的资金 [66][67] - 管理层对Shield V2的性能提升表示信心,并计划进行监管级别的临床试验 [40][41][42] 问答环节重要的提问和回答 问题1 **Tejas Savant 提问** 询问Guardant360 LDT和CDx的占比变化以及独立CPT编码对私人保险报销的影响 [72][73][74][75][76] **Michael Bell 回答** CDx占比略有提升,独立CPT编码有望提升透明度并简化私人保险报销 [73][74][75][76] 问题2 **Dan Arias 提问** 询问全年临床检测量增长目标是否维持在高30%至低40% [81][82] **Michael Bell 回答** 全年临床检测量增长仍预计达到高30%至低40% [82] 问题3 **AmirAli Talasaz 回答** Shield V2相比V1在检测高级腺瘤和早期癌症方面有显著提升,公司计划进行监管级别的临床试验 [137][138][139][140]